Understanding cell entry pathway of Adenovirus type 26: way of improving vaccine vectors
Principal investigator
Adenovirus (AdV) based vectors have potential translational and commercial values and are currently studied as vectors for DNA transfer and vaccination. Adenovirus type 26 (AdV26) has fundamental differences in immunogenicity from other AdV vectors, which might give it advantage over other AdV serotypes in vaccine vector development. To the best of our knowledge there are no reports linking AdV26 entry pathway with induction of innate immune response, underlining the need for studying infection pathway used by AdV26. Accordingly, the main objectives of this study are investigating AdV26 receptor usage, binding, internalization, intracellular trafficking of AdV26 and AdV26 mediated induction of innate immune response inin vitrosettings.
Other associates
Dr.sc. Andreja Ambriović Ristov, Institut Ruđer Bošković, Zagreb
Dr.sc. Mladen Krajačić, Faculty of Science, Sveučilište u Zagrebu
Dr.sc. Jelena Knežević, Institut Ruđer Bošković, Zagreb
Dr.sc. Jelena Ruščić, Faculty of Science, Sveučilište u Zagrebu
mag. ing. mol. biotechn. Davor Nestić, PhD candidate, Institut Ruđer Bošković, Zagreb
Jolien Van den Bosch, ERASMUS student, Hogeschool Gent, Belgium
Consultants:
Dr.sc. Jerome Custers, Sr Scientific Director, Head of Vaccine Generation Janssen Infectious Diseases and Vaccines, Crucell Holland BV, The Netherlands
Dr.sc. Andrew Baker, BHF Professor of Translational Cardiovascular Sciences Centre for Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK